2-Trimethylsilylethyl 2,4-bis(ethoxymethoxy)-6-methylbenzoate | 867367-88-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Trimethylsilylethyl 2,4-bis(ethoxymethoxy)-6-methylbenzoate
• CAS: 867367-88-2
• 化学式: C₁₉H₃₂O₆Si
• 分子量: 384.545
• InChiKey: ZDBFYNIOQFIJQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.24
• 重原子数：
  26
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  63.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-Trimethylsilylethyl 2,4-bis(ethoxymethoxy)-6-methylbenzoate 在 四丁基氟化铵 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 为溶剂， 反应 47.0h， 生成 2-((E)-3-((4S,5S)-5-((1R,5R,E)-1-(benzoyloxy)-2-fluoro-5-hydroxyhex-2-en-1-yl)-2,2-dimethyl-1,3-dioxolan-4-yl)prop-1-en-1-yl)-4,6-bis(ethoxymethoxy)benzoic acid
  参考文献：
  名称：

  [EN] IRREVERSIBLE INHIBITORS USEFUL FOR THE TREATMENT OF KINASE-RELATED PATHOLOGIES
  [FR] INHIBITEURS IRRÉVERSIBLES UTILISÉS POUR TRAITER DES PATHOLOGIES ASSOCIÉES À UNE KINASE

  摘要：

  本发明提供了具有激酶抑制活性的新化合物(I)，可用于治疗癌症。

  公开号：

  WO2011036299A1
• 作为产物：
  描述：

  2,4-二羟基-6-甲基苯甲醛 在 4-二甲氨基吡啶 、 sodium chlorite 、 sodium dihydrogenphosphate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 15.5h， 生成 2-Trimethylsilylethyl 2,4-bis(ethoxymethoxy)-6-methylbenzoate
  参考文献：
  名称：

  Radicicol（monorden）和Pochonin C的溶液和固相合成。

  摘要：

  报道了软骨素C和radicicol的模块化合成。两种天然产物分别从三个易得的片段中分七个步骤和八个步骤制备。这些化合物的替代合成是通过结合聚合物的试剂和固相反应实现的。研究了两种天然产物的构象，并通过2D NMR光谱进行了比较。

  DOI：

  10.1002/chem.200500160

文献信息

• Synthesis of a Resorcylic Acid Lactone (RAL) Library Using Fluorous-Mixture Synthesis and Profile of its Selectivity Against a Panel of Kinases
  作者：Rajamalleswaramma Jogireddy、Pierre-Yves Dakas、Gaëlle Valot、Sofia Barluenga、Nicolas Winssinger

  DOI：10.1002/chem.200901375

  日期：2009.11.2

  A library of resorcylic acid lactones (RAL) containing a cis‐enone moiety targeting kinases bearing a cysteine residue within the ATP‐binding pocket was prepared using a fluorous‐mixture synthesis and evaluated against a panel of 19 kinases thus providing important structure–activity trends. Two new analogues were then profiled for their selectivity against a panel of 402 kinases providing the broadest

  使用氟混合物合成方法制备了含有顺式-烯酮部分靶向激酶的顺式-烯酮部分文库的间苯二酸内酯（RAL），该激酶在ATP结合袋中带有半胱氨酸残基，并针对一组19种激酶进行了评估，从而提供了重要的结构-活性趋势。然后，针对两个新的类似物针对一组402种激酶的选择性进行了分析，从而对该药效基团的选择性进行了最广泛的评估。
• Synthesis of pochoxime prodrugs as potent HSP90 inhibitors
  作者：Cuihua Wang、Sofia Barluenga、Girish K. Koripelly、Jean-Gonzague Fontaine、Ruihong Chen、Jin-Chen Yu、Xiaodong Shen、John C. Chabala、James V. Heck、Allan Rubenstein、Nicolas Winssinger

  DOI：10.1016/j.bmcl.2009.04.030

  日期：2009.7

  Pochoximes are potent inhibitors of heat shock protein 90 (HSP90) based on the radicicol pharmacophores. Herein we present a pharmacokinetics and pharmacodynamics evaluation of this compound series as well as a phosphate prodrug strategy to facilitate formulation and improve oral bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.
• Divergent Synthesis of a Pochonin Library Targeting HSP90 and In Vivo Efficacy of an Identified Inhibitor
  作者：Sofia Barluenga、Cuihua Wang、Jean-Gonzague Fontaine、Kaïss Aouadi、Kristin Beebe、Shinji Tsutsumi、Len Neckers、Nicolas Winssinger

  DOI：10.1002/anie.200800233

  日期：2008.5.26

  The heat shock protein 90 (HSP90) has emerged as one of the most exciting therapeutic target in recent years.[1, 2] Despite the seemingly ubiquitous function of this constitutively expressed chaperone, its role in stabilizing conformationally labile proteins has implications in pathologies ranging from oncology to neurodegenerative diseases. Most of HSP90’s endogenous clients[3] are key regulators of cell signaling which are destabilized and degraded in the absence of HSP90’s chaperoning activity. The dependence of transformed cells on HSP90 is further heightened by the fact that many oncogenic mutations, while increasing the activity of pro-growth signaling pathways, are less stable than their wild type counterpart and have an increased dependence on HSP90’s chaperoning activity.[4] A clinically relevant example is the heightened dependence of drug resistant Bcr-Abl mutants on HSP90’s activity and the fact that HSP90 inhibitors in combination with Abl inhibitors remain effective against such mutants.[5, 6] Accordingly, HSP90 inhibition provides a broad and effective target for anticancer treatment. Furthermore, HSP90 inhibitors can act synergistically with a cytotoxic agent.[7] HSP90 is also implicated in regulating the fate of a number of conformationally unstable proteins which underlie the development of neurodegenerative diseases.[8] It has been shown that HSP90 inhibitors can reduce protein aggregates in cellular and animal models of Huntington disease,[9] spinal and bulbar muscular atrophy,[10] Parkinson disease,[11] and other Tau protein-related neurodegenerative diseases.[12]